Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience

被引：0
|
作者：
Grilo, I. T. [1 ]
Couto, M. E. [2 ]
Freitas, J. F. [3 ]
Pereira, D. P. [2 ]
Moreira, C. [2 ]
Chacim, S. [2 ]
Domingues, N. [2 ]
Santo, A. E. [2 ]
Martins, A. [2 ]
Viterbo, L. [2 ]
Oliveira, I. [2 ]
Moreira, I. [2 ]
Mariz, J. M. [2 ]
机构：
[1] Ctr Hosp Tras Os Montes & Alto Douro, Oncohematol Dept, EPE, Chaves, Portugal
[2] IPO Porto, Porto, Portugal
[3] IPO Porto, Hematooncol Dept, Porto, Portugal
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz413.060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
    Hoy, Sheridan M.
    McKeage, Kate
    [J]. DRUGS, 2010, 70 (14) : 1819 - 1829
  • [22] Management of relapsed/refractory mantle cell lymphoma
    Alzahrani, Musa
    Villa, Diego
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1044 - 1054
  • [23] TemsirolimusIn Relapsed and/or Refractory Mantle Cell Lymphoma
    Sheridan M. Hoy
    Kate McKeage
    [J]. Drugs, 2010, 70 : 1819 - 1829
  • [24] Dismantling relapsed/refractory mantle cell lymphoma
    Ryan, Christine E.
    Kumar, Anita
    [J]. BLOOD REVIEWS, 2024, 67
  • [25] BENDAMUSTINE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: RETROSPECTIVE ANALYSIS OF THE SPANISH EXPERIENCE
    Garcia-Noblejas, A.
    Navarro Matilla, B.
    Gonzalez Lopez, T.
    Da Silva Rodriguez, C.
    Sanchez Blanco, J. J.
    Ramirez Sanchez, M. J.
    Nicolas, C.
    Perez Fernandez, R.
    Sanchez Gonzalez, B.
    Domingo Domenech, E.
    Panizo, C.
    Macia, S.
    Fernandez Fonseca, E.
    Cannata-Ortiz, J.
    Ona Navarrete, R.
    Arranz Saez, R.
    [J]. HAEMATOLOGICA, 2012, 97 : 102 - 102
  • [26] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [27] Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis
    Yi, J. H.
    Kim, W. S.
    Kim, S. J.
    Yoon, D. H.
    Suh, C.
    Chang, M. H.
    Yang, D. H.
    Jo, J-C.
    Hyun, S. Y.
    Eom, H-S.
    Lee, J-O.
    Kwon, J. H.
    Han, S. H.
    Lee, S-S.
    Kwak, J-Y.
    Kim, S. H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [28] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [29] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    McBride, Ali
    Slack, Marion
    Abraham, Ivo
    [J]. BLOOD, 2020, 136
12345